Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EAGLES: Bevacizumab in Elderly Advanced Non-Squamous NSCLC
NCT01077713Phase 2Completed
- Sponsor
- Roche
- Start
- Feb 2010
- Primary completion
- Jul 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (2 arms), sponsored by Roche. Primary endpoint: Percentage of Participants Alive and Without Progressive Disease at Month 6. Started Feb 2010; status: completed.
02
Drugs
bevacizumab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT01077713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01077713.